Literature DB >> 9655566

The role of combination therapy in the treatment of hypertension.

M Moser1, H R Black.   

Abstract

Only approximately 40% to 50% of hypertensive patients will achieve goal blood pressures of <140/ 90 mm Hg with monotherapy, regardless of the medication used. Fixed-dose combination therapy with two different classes of antihypertensive agents will achieve goal pressures in more than 70%. The sixth Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure has suggested that the use of combination therapy is appropriate as initial treatment. The advantages of combinations include: 1) greater blood pressure decrease and response rates than monotherapy; 2) fewer side effects with small doses of two drugs than with large doses of one agent; 3) improved adherence to treatment; and 4) possibly lower cost of therapy. Many different combinations of diuretics and beta-blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, as well as ACE inhibitors and calcium antagonists are available. Two of these, Ziac and Capozide, have been approved as initial therapy. It is possible that the number of hypertensive individuals controlled at goal blood pressure levels will be increased if combination therapy is used as initial treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655566     DOI: 10.1016/s0895-7061(98)00060-0

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  11 in total

Review 1.  Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.

Authors:  Richard B R Muijsers; Monique P Curran; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.

Authors:  Roberto Fogari; Amedeo Mugellini; Paola Preti; Annalisa Zoppi; Giuseppe Derosa
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

3.  Antihypertensive Prescribing Pattern in Older Adults: Implications of Age and the Use of Dual Single-Pill Combinations.

Authors:  Khalid A J Al Khaja; Henry James; Sindhan Veeramuthu; Yasin I Tayem; Kannan Sridharan; Reginald P Sequeira
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-12-03

4.  Effectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm study.

Authors:  Roberto Fogari; Annalisa Zoppi; Amedeo Mugellini; Paola Preti; Maurizio Destro; Andrea Rinaldi; Giuseppe Derosa
Journal:  Curr Ther Res Clin Exp       Date:  2008-02

Review 5.  Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?

Authors:  Matthew R Weir; George L Bakris
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-02       Impact factor: 3.738

Review 6.  Update on the management of hypertension: recent clinical trials and the JNC 7.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

Review 7.  Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies.

Authors:  C Ventika S Ram
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-10       Impact factor: 3.738

8.  Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches.

Authors:  George L Bakris; Matthew R Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

9.  Combination therapy for hypertension: an update.

Authors:  M Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

Review 10.  Rationale for combination therapy in the management of hypertension.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.